# Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis

> **NCT01503021** · PHASE3 · COMPLETED · sponsor: **Rockwell Medical Technologies, Inc.** · enrollment: 718 (actual)

## Conditions studied

- End Stage Renal Disease
- Chronic Kidney Disease

## Interventions

- **DRUG:** SFP
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01503021
- **Lead sponsor:** Rockwell Medical Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 718 (ACTUAL)
- **Last updated:** 2016-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01503021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01503021, "Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01503021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*